Swissmedic grants approval for Sobi’s Elocta to treat haemophilia A

Specialty healthcare company Swedish Orphan Biovitrum (Sobi) has received approval from the Swiss Agency for Therapeutic Products, Swissmedic, for its Elocta (rFVIIIFc) to treat patients affected with haemophilia A.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news